Monoclonal antibody therapy in sinonasal disease

Sergio E. Chiarella, Hendrik Sy, Anju Tripathi Peters*

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Chronic rhinosinusitis (CRS) affects 12.5% of the U.S. population. CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.

Original languageEnglish (US)
Pages (from-to)93-95
Number of pages3
JournalAmerican Journal of Rhinology and Allergy
Volume31
Issue number2
DOIs
StatePublished - Mar 1 2017

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Monoclonal antibody therapy in sinonasal disease'. Together they form a unique fingerprint.

  • Cite this